Novo Nordisk’s (NVO) weight management medications Ozempic and Wegovy — intended for people struggling with type 2 diabetes and obesity, respectively — have shot to popularity, not least, because celebrities are open about using them.
But these weight-loss drugs might not only reduce waistlines; they could reduce bottom lines, too.
As demand for Ozempic and Wegovy surges, the food and retail industries are on high alert, concerned that the appetite suppressants may put pressure on fast-food menus and snack aisles.
Walmart (WMT) added fuel to the fire when its U.S. CEO John Furner said the retail giant was seeing the effects of people taking weight-loss drugs reflected in food shopping. The company noticed the trend by juxtaposing its pharmacy data with grocery trends: fewer units of food, fewer calories.
And this may just be beginning. Analysts at Morgan Stanley (MS) project as many as 24 million Americans — 7% of the U.S. population — will use weight-loss drugs by 2035.
For investors and industry stalwarts the rise of weight management drugs is a curveball that could reshape the food and retail landscape as high-calorie food products lose appeal.
However, Walmart also noted that overall sales from shoppers on the weight-loss drugs were actually higher. So while food spending might see a dip, it could be a boon to retailers in other sectors.
Looking for more stories like this? Check out On the Money — SoFi’s one-stop-shop for news, trends, and tips!
Please understand that this information provided is general in nature and shouldn’t be construed as a recommendation or solicitation of any products offered by SoFi’s affiliates and subsidiaries. In addition, this information is by no means meant to provide investment or financial advice, nor is it intended to serve as the basis for any investment decision or recommendation to buy or sell any asset. Keep in mind that investing involves risk, and past performance of an asset never guarantees future results or returns. It’s important for investors to consider their specific financial needs, goals, and risk profile before making an investment decision.
No brands or products mentioned are affiliated with SoFi, nor do they endorse or sponsor this content.
Communication of SoFi Wealth LLC an SEC Registered Investment Advisor
SoFi isn’t recommending and is not affiliated with the brands or companies displayed. Brands displayed neither endorse or sponsor this article. Third party trademarks and service marks referenced are property of their respective owners.